🔗 Share this article

As the United States continues making unprecedented changes to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccinations in the global health crisis and has concentrated on potential deaths after COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Immunization Schedule

Public health authorities had intended to unveil major changes to the childhood immunization program recently, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US out of alignment with a large portion of the global community with little proof for benefit. The planned update has been postponed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

Consolidating Power at the FDA

This interim role might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon dismantling previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting certain childhood immunization guidelines in the US in order to be more in line with Denmark, a nation with universal health coverage and a citizenry roughly the size of Wisconsin’s.

So far comments, she has continued to focus on vaccination policy – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no obvious background in medication creation, oversight or administrative roles, which has been standard for past directors of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Former directors of the center would “grasp laws and regulations and the underlying principles of medication creation”, noted Janet Woodcock. “Clearly, she lacks the type of experience that former directors who led the center have had.”

CDER has an immense range of responsibilities at the agency, Woodcock stated.

“Many people just focuses on the innovative therapies, but the generic drug division clears thousands of generic medications. There’s a biosimilars division, OTC medication office and so forth, and all of those have to be supervised,” Dr. Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the position, which oversees more than 5,000 employees. “It is a huge leadership role, if you do it right,” Woodcock concluded.

Response and Contentious Initiatives

When asked about inquiries about Høeg’s qualifications and whether this selection represents more teamwork among FDA leaders on vaccines, a spokesperson stated that the “inquiries are based on flawed assumptions”.

“Her experience matches the duties of her position,” the representative stated, pointing to the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a contentious one-day drug-approval program that reportedly concerned her former heads. “How are these drugs being selected for this voucher program? Who takes the calls?” Dr. Howard asked. “There is a lot of secrecy going on at the agency right now.”

Broadly speaking, he said, “the agency seems to be moving towards less stringent rules of most medications, with the exception of shots.”

Documented History on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, track record, Howard said. She published a study using non-validated public submissions to estimate the incidence of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to suggest Covid vaccinations are riskier than they are.

Part of her “wish list” for the current administration encompassed altering rules for new vaccines and ending “optional” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has reportedly proposed excluding adolescent males from receiving COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her conclusions and works backwards to fit the science in a highly disingenuous, dishonest fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with fellow contrarians, {like|